(Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic
Open Access
- 18 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 186 (2), 577-583
- https://doi.org/10.1007/s10549-021-06112-y
Abstract
Purpose To identify factors associated with (perceived) access to health care among (ex-)breast cancer patients during the COVID-19 pandemic. Methods Cross-sectional study within a large prospective, multicenter cohort of (ex-)breast cancer patients, i.e., UMBRELLA. All participants enrolled in the UMBRELLA cohort between October 2013 and April 2020 were sent a COVID-19-specific survey, including the Hospital Anxiety and Depression Scale (HADS) questionnaire. Results In total, 1051 (66.0%) participants completed the survey. During COVID-19, 284 (27.0%) participants reported clinically relevant increased levels of anxiety and/or depression, i.e., total HADS score ≥ 12. Participants with anxiety and/or depression reported statistically significant higher barriers to contact their general practitioner (47.5% vs. 25.0%, resp.) and breast cancer physicians (26.8% vs. 11.2%, resp.) compared to participants without these symptoms. In addition, a higher proportion of participants with anxiety and/or depression reported that their current treatment or (after)care was affected by COVID-19 compared to those without these symptoms (32.7% vs. 20.5%, resp.). Factors independently associated with symptoms of anxiety and/or depression during COVID-19 were pre-existent anxiety (OR 6.1, 95% CI 4.1–9.2) or depression (OR 6.0, 95% CI 3.5–10.2). Conclusion During the COVID-19 pandemic, (ex-)breast cancer patients with symptoms of anxiety and/or depression experience higher barriers to contact health care providers. Also, they more often report that their health care was affected by COVID-19. Risk factors for anxiety and/or depression during COVID-19 are pre-existent symptoms of anxiety or depression. Extra attention—including mental health support—is needed for this group.Keywords
This publication has 14 references indexed in Scilit:
- Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands CommentThe Lancet Oncology, 2020
- The psychological impact of quarantine and how to reduce it: rapid review of the evidenceThe Lancet, 2020
- Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and researchJournal of Clinical Epidemiology, 2020
- The Trials within Cohorts design faced methodological advantages and disadvantages in the exercise oncology settingJournal of Clinical Epidemiology, 2019
- Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patientsBreast Cancer Research and Treatment, 2017
- The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results.Breast Cancer Research and Treatment, 2017
- Intolerance of uncertainty, appraisals, coping, and anxiety: The case of the 2009 H1N1 pandemicBritish Journal of Health Psychology, 2013
- A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjectsPsychological Medicine, 1997
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983